PL2906248T3 - Pirolobenzodiazepiny i ich koniugaty - Google Patents
Pirolobenzodiazepiny i ich koniugatyInfo
- Publication number
- PL2906248T3 PL2906248T3 PL13780099T PL13780099T PL2906248T3 PL 2906248 T3 PL2906248 T3 PL 2906248T3 PL 13780099 T PL13780099 T PL 13780099T PL 13780099 T PL13780099 T PL 13780099T PL 2906248 T3 PL2906248 T3 PL 2906248T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrrolobenzodiazepines
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712924P | 2012-10-12 | 2012-10-12 | |
| EP13780099.1A EP2906248B1 (en) | 2012-10-12 | 2013-10-11 | Pyrrolobenzodiazepines and conjugates thereof |
| PCT/EP2013/071235 WO2014057073A1 (en) | 2012-10-12 | 2013-10-11 | Pyrrolobenzodiazepines and conjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2906248T3 true PL2906248T3 (pl) | 2019-05-31 |
Family
ID=49474386
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13780099T PL2906248T3 (pl) | 2012-10-12 | 2013-10-11 | Pirolobenzodiazepiny i ich koniugaty |
| PL18187765T PL3470086T3 (pl) | 2012-10-12 | 2013-10-11 | Pirolobenzodiazepiny i ich koniugaty |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18187765T PL3470086T3 (pl) | 2012-10-12 | 2013-10-11 | Pirolobenzodiazepiny i ich koniugaty |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9415117B2 (pl) |
| EP (2) | EP2906248B1 (pl) |
| JP (2) | JP6367811B2 (pl) |
| KR (3) | KR20150083994A (pl) |
| CN (2) | CN110256469B (pl) |
| AU (1) | AU2013328674B2 (pl) |
| BR (1) | BR112015008251B1 (pl) |
| CA (2) | CA3060520C (pl) |
| CY (2) | CY1121390T1 (pl) |
| DK (2) | DK2906248T3 (pl) |
| ES (2) | ES2713164T3 (pl) |
| HR (2) | HRP20190366T1 (pl) |
| HU (2) | HUE052835T2 (pl) |
| LT (2) | LT2906248T (pl) |
| MX (2) | MX366303B (pl) |
| NZ (2) | NZ745069A (pl) |
| PL (2) | PL2906248T3 (pl) |
| PT (2) | PT3470086T (pl) |
| RS (2) | RS61294B1 (pl) |
| SI (2) | SI2906248T1 (pl) |
| SM (2) | SMT201900144T1 (pl) |
| TR (1) | TR201902494T4 (pl) |
| WO (1) | WO2014057073A1 (pl) |
| ZA (1) | ZA201501781B (pl) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| MX368648B (es) | 2010-04-15 | 2019-10-09 | Seattle Genetics Inc | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas. |
| NZ602932A (en) | 2010-04-15 | 2014-08-29 | Seattle Genetics Inc | Targeted pyrrolobenzodiazapine conjugates |
| MX341524B (es) | 2011-09-20 | 2016-08-24 | Medimmune Ltd | Pirrolobenzodiazepinas como compuestos pbd dimericos asimetricos para inclusion en conjugados dirigidos. |
| AU2012322613B2 (en) | 2011-10-14 | 2016-04-21 | Medimmune Limited | Pyrrolobenzodiazepines and targeted conjugates |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| EP2751110B1 (en) | 2011-10-14 | 2017-04-19 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases |
| KR101891859B1 (ko) | 2011-10-14 | 2018-08-24 | 메디뮨 리미티드 | 피롤로벤조디아제핀 |
| KR20150039818A (ko) * | 2012-08-02 | 2015-04-13 | 제넨테크, 인크. | 항-etbr 항체 및 면역접합체 |
| EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| WO2014057122A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| SMT201800346T1 (it) * | 2012-10-12 | 2018-09-13 | Medimmune Ltd | Coniugati pirrolobenzodiazepina-anticorpo |
| PT2906298T (pt) * | 2012-10-12 | 2018-12-28 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpos |
| SI2906253T1 (sl) | 2012-10-12 | 2018-11-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo proti PSMA |
| US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP2906249B1 (en) | 2012-10-12 | 2018-06-27 | MedImmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| ES2713164T3 (es) | 2012-10-12 | 2019-05-20 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
| WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| JP6307519B2 (ja) | 2012-12-21 | 2018-04-04 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピンおよびその結合体 |
| CN110627797A (zh) | 2012-12-21 | 2019-12-31 | 麦迪穆有限责任公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| EP2968596B1 (en) | 2013-03-13 | 2019-03-06 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CA2914189C (en) * | 2013-06-21 | 2023-03-14 | Innate Pharma | Enzymatic conjugation of polypeptides |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| PE20170935A1 (es) | 2014-09-12 | 2017-07-13 | Genentech Inc | Anticuerpos anti-her2 e inmunoconjugados |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| PE20171185A1 (es) | 2015-01-14 | 2017-08-22 | Bristol Myers Squibb Co | Dimeros de benzodiazepina unidos con puentes de heteroarileno, conjugados de estos, y sus metodos de preparacion y uso |
| US9527871B2 (en) | 2015-01-14 | 2016-12-27 | Bristol-Myers Squibb Company | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
| GB201506402D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506405D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506394D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| CA2990030A1 (en) | 2015-06-23 | 2016-12-29 | Bristol-Myers Squibb Company | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| TWI726942B (zh) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| WO2017184942A1 (en) | 2016-04-21 | 2017-10-26 | Abbvie Stemcentrx Llc | Novel anti-bmpr1b antibodies and methods of use |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| TW201808936A (zh) | 2016-05-18 | 2018-03-16 | 美商梅爾莎納醫療公司 | 吡咯并苯并二氮呯類及其共軛物 |
| US10526294B2 (en) | 2016-06-24 | 2020-01-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201619490D0 (en) * | 2016-11-17 | 2017-01-04 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| EP3348560A1 (en) * | 2017-01-16 | 2018-07-18 | Spago Nanomedical AB | Chemical compounds for coating of nanostructures |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| ES2871001T3 (es) | 2017-02-08 | 2021-10-28 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepinas y anticuerpos |
| WO2018192944A1 (en) | 2017-04-18 | 2018-10-25 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| ES2988683T3 (es) | 2017-06-14 | 2024-11-21 | Adc Therapeutics Sa | Pautas posológicas para la administración de un CAF anti-CD19 |
| SG11202000358YA (en) | 2017-08-18 | 2020-02-27 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| AU2018342527B2 (en) | 2017-09-29 | 2024-06-27 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| CN111417409B (zh) | 2017-11-14 | 2022-07-08 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂䓬缀合物 |
| WO2019104289A1 (en) | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| CU24558B1 (es) * | 2017-11-28 | 2021-12-08 | Ct Inmunologia Molecular | Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados |
| JP2021506883A (ja) | 2017-12-21 | 2021-02-22 | メルサナ セラピューティクス インコーポレイテッド | ピロロベンゾジアゼピン抗体結合体 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| WO2019189453A1 (en) | 2018-03-28 | 2019-10-03 | Mitsubishi Tanabe Pharma Corporation | DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201811364D0 (en) * | 2018-07-11 | 2018-08-29 | Adc Therapeutics Sa | Combination therapy |
| GB201902495D0 (en) | 2019-02-25 | 2019-04-10 | Medimmune Ltd | Methods of synthesis and intermediates |
| MX2021010477A (es) | 2019-03-15 | 2021-10-01 | Medimmune Ltd | Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer. |
| AU2020265679A1 (en) | 2019-04-30 | 2021-12-23 | Senti Biosciences, Inc. | Chimeric receptors and methods of use thereof |
| AU2020292965A1 (en) * | 2019-06-10 | 2022-01-27 | Adc Therapeutics Sa | Combination therapy comprising an anti-CD19 antibody drug conjugate and a PI3K inhibitor or a secondary agent |
| MX2022001812A (es) | 2019-08-12 | 2022-03-11 | Regeneron Pharma | Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos. |
| WO2021080608A1 (en) | 2019-10-25 | 2021-04-29 | Medimmune, Llc | Branched moiety for use in conjugates |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| JP2024507823A (ja) * | 2021-02-19 | 2024-02-21 | ヤンセン バイオテツク，インコーポレーテツド | 免疫監視を増強するために制御性ｔ細胞を標的化するための材料及び方法 |
| KR102285542B1 (ko) | 2021-03-09 | 2021-08-04 | 주식회사 레젠 | 투광등용 리플렉터 및 이를 가진 투광등 |
| AU2023232164A1 (en) * | 2022-03-11 | 2024-08-08 | Sigma-Aldrich Co. Llc | Pyrrolobenzodiazepine intermediates and uses thereof |
| EP4548932A1 (en) | 2022-06-30 | 2025-05-07 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| CN117624167A (zh) * | 2022-08-18 | 2024-03-01 | 四川大学 | 吡咯并苯并二氮杂卓-蒽酰亚胺杂交分子及其制备方法和用途 |
| WO2025096716A1 (en) | 2023-11-01 | 2025-05-08 | Incyte Corporation | Anti-mutant calreticulin (calr) antibody-drug conjugates and uses thereof |
Family Cites Families (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3361742A (en) | 1964-12-07 | 1968-01-02 | Hoffmann La Roche | 5-oxo-1h-pyrrolo-[2, 1-c][1, 4]-benzodiazepin-2-crylamides |
| US3523941A (en) | 1967-03-06 | 1970-08-11 | Hoffmann La Roche | Benzodiazepine compounds and process for their preparation |
| US3524849A (en) | 1967-10-27 | 1970-08-18 | Hoffmann La Roche | Process for the preparation of pyrrolo-benzodiazepine acrylamides and intermediates useful therein |
| JPS4843755B1 (pl) | 1969-06-26 | 1973-12-20 | ||
| FR2027356A1 (en) | 1968-12-30 | 1970-09-25 | Fujisawa Pharmaceutical Co | Benzodiazepinone antibiotics |
| IL33558A (en) | 1968-12-30 | 1973-10-25 | Fujisawa Pharmaceutical Co | Antibiotic pyrrolo-benzodiazepine compound,its derivatives and processes for their production |
| JPS5382792U (pl) | 1976-12-10 | 1978-07-08 | ||
| JPS585916B2 (ja) | 1977-12-27 | 1983-02-02 | 株式会社ミドリ十字 | 新規ベンゾジアゼピン系化合物 |
| JPS5615289A (en) | 1979-07-17 | 1981-02-14 | Green Cross Corp:The | Novel benzodiazepinnbased compound 3 |
| JPH0353356Y2 (pl) | 1981-02-06 | 1991-11-21 | ||
| CA1185602A (en) | 1981-02-27 | 1985-04-16 | Emilio Kyburz | Imidazodiazepines |
| CA1173441A (en) | 1981-02-27 | 1984-08-28 | Hoffmann-La Roche Limited | Imidazodiazepines |
| CA1184175A (en) | 1981-02-27 | 1985-03-19 | Walter Hunkeler | Imidazodiazepines |
| JPS58180487A (ja) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 抗生物質ｄｃ−８１およびその製造法 |
| JPS58180487U (ja) | 1982-05-28 | 1983-12-02 | 松下電工株式会社 | 光線式報知器の組立体 |
| US4427588A (en) | 1982-11-08 | 1984-01-24 | Bristol-Myers Company | Process for conversion of oxotomaymycin to tomaymycin |
| US4427587A (en) | 1982-11-10 | 1984-01-24 | Bristol-Myers Company | Total synthesis of antitumor antibiotics BBM-2040A and BBM-2040B |
| JPS59152329A (ja) | 1983-02-17 | 1984-08-31 | Green Cross Corp:The | 局所障害抑制剤 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| FR2586683B1 (fr) | 1985-08-29 | 1988-07-01 | Centre Nat Rech Scient | Nouveaux derives de neothramycine, leur procede de preparation et leur application en tant que medicaments |
| US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
| JP2660201B2 (ja) | 1988-08-05 | 1997-10-08 | 塩野義製薬株式会社 | 新規ピロロ［１，４］ベンゾジアゼピン誘導体および老人性痴呆薬 |
| FR2676230B1 (fr) | 1991-05-07 | 1993-08-27 | Centre Nat Rech Scient | Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant. |
| GB9205051D0 (en) | 1992-03-09 | 1992-04-22 | Cancer Res Campaign Tech | Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them |
| FR2696176B1 (fr) | 1992-09-28 | 1994-11-10 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| GB9316162D0 (en) | 1993-08-04 | 1993-09-22 | Zeneca Ltd | Fungicides |
| JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| JP4568429B2 (ja) | 1998-07-08 | 2010-10-27 | イー インク コーポレイション | マイクロカプセル化された電気泳動デバイスにおいて改良されたカラーを得る方法 |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| DK1413582T3 (da) | 1998-08-27 | 2006-07-17 | Spirogen Ltd | Dimere pyrrolobenzodiazepiner |
| GB9818730D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
| GB9818732D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
| US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
| JP2003518075A (ja) | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | 生理活性化合物の消失半減期延長のための方法及び組成物 |
| US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| EP1320522B8 (en) | 2000-09-19 | 2006-02-01 | Moses Lee | Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| US6660856B2 (en) | 2002-03-08 | 2003-12-09 | Kaohsiung Medical University | Synthesis of pyrrolo[2,1-c][1,4]benzodiazepine analogues |
| SI2357006T1 (sl) | 2002-07-31 | 2016-01-29 | Seattle Genetics, Inc. | Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni |
| US20040138269A1 (en) | 2002-10-11 | 2004-07-15 | Sugen, Inc. | Substituted pyrroles as kinase inhibitors |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| EP1608664B1 (en) | 2003-03-31 | 2009-01-28 | Council of Scientific and Industrial Research | Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| GB0416511D0 (en) | 2003-10-22 | 2004-08-25 | Spirogen Ltd | Pyrrolobenzodiazepines |
| ATE516288T1 (de) | 2003-10-22 | 2011-07-15 | Us Gov Health & Human Serv | Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| WO2005079479A2 (en) | 2004-02-17 | 2005-09-01 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| GB0404574D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Amino acids |
| ES2398975T3 (es) * | 2004-03-01 | 2013-03-25 | Spirogen Sàrl | Derivados de 11-hidroxi-5H-pirrolo[2,1-c][1,4]benzodiazepin-5-ona como intermedios clave para la preparación de pirrolobenzodiazepinas sustituidas en C2 |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| DE102004010943A1 (de) | 2004-03-03 | 2005-09-29 | Degussa Ag | Verfahren zur Herstellung von N-geschützten 4-Ketprolinderivaten |
| JP5166861B2 (ja) | 2004-03-09 | 2013-03-21 | スピロゲン リミティッド | ピロロベンゾジアゼピン |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| EP1831418A2 (en) | 2004-12-24 | 2007-09-12 | Showa Denko Kabushiki Kaisha | Production method of thermoelectric semiconductor alloy, thermoelectric conversion module and thermoelectric power generating device |
| AU2006210724A1 (en) | 2005-02-03 | 2006-08-10 | Antitope Limited | Human antibodies and proteins |
| JP5122441B2 (ja) | 2005-04-19 | 2013-01-16 | シアトル ジェネティックス， インコーポレイテッド | ヒト化抗ｃｄ７０結合剤およびその使用 |
| SI1879901T1 (sl) | 2005-04-21 | 2010-04-30 | Spirogen Ltd | Pirolobenzodiazepini |
| US20070154906A1 (en) | 2005-10-05 | 2007-07-05 | Spirogen Ltd. | Methods to identify therapeutic candidates |
| ATE427949T1 (de) | 2005-10-05 | 2009-04-15 | Spirogen Ltd | 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung |
| SI1934174T1 (sl) | 2005-10-07 | 2011-08-31 | Exelixis Inc | Inhibitorji MEK in postopki za njihovo uporabo |
| DK1813614T3 (da) | 2006-01-25 | 2012-01-23 | Sanofi Sa | Cytotoksiske midler, der omfatter nye tomaymycinderivater |
| ZA200900545B (en) | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| WO2008050140A2 (en) | 2006-10-27 | 2008-05-02 | Spirogen Limited | Compounds for treatment of parasitic infection |
| CA2699837C (en) | 2006-12-01 | 2017-06-13 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| JP5290276B2 (ja) | 2007-05-08 | 2013-09-18 | ジェネンテック， インコーポレイテッド | システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体 |
| SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
| CN101835803B (zh) | 2007-10-19 | 2016-05-25 | 健泰科生物技术公司 | 半胱氨酸改造的抗tenb2抗体和抗体药物偶联物 |
| GB0722088D0 (en) | 2007-11-09 | 2007-12-19 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0722087D0 (en) | 2007-11-09 | 2007-12-19 | Spirogen Ltd | Polyamides |
| CN102083460A (zh) * | 2008-01-18 | 2011-06-01 | 米迪缪尼有限公司 | 用于位点特异性偶联的半胱氨酸工程化抗体 |
| CA2718942A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
| CN102176873A (zh) | 2008-10-15 | 2011-09-07 | 捷迈有限公司 | 髓内钉 |
| GB0819097D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| EP3100745B1 (en) | 2009-02-05 | 2018-04-18 | Immunogen, Inc. | Novel benzodiazepine derivatives |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| JP2013505944A (ja) | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス， インコーポレイテッド | Ｄｒ５リガンド薬物結合体 |
| EP2534158B1 (en) | 2010-02-09 | 2014-01-08 | Bristol-Myers Squibb Company | Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| MX368648B (es) * | 2010-04-15 | 2019-10-09 | Seattle Genetics Inc | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas. |
| WO2011130615A2 (en) | 2010-04-15 | 2011-10-20 | Dr. Reddy's Laboratories Ltd. | Preparation of lacosamide |
| NZ602932A (en) * | 2010-04-15 | 2014-08-29 | Seattle Genetics Inc | Targeted pyrrolobenzodiazapine conjugates |
| BR112012026213B1 (pt) | 2010-04-15 | 2021-12-28 | Medimmune Limited | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa |
| EP2675479B1 (en) | 2011-02-15 | 2016-01-13 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| MX341524B (es) * | 2011-09-20 | 2016-08-24 | Medimmune Ltd | Pirrolobenzodiazepinas como compuestos pbd dimericos asimetricos para inclusion en conjugados dirigidos. |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| KR101891859B1 (ko) | 2011-10-14 | 2018-08-24 | 메디뮨 리미티드 | 피롤로벤조디아제핀 |
| SG11201401406YA (en) | 2011-10-14 | 2014-05-29 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| AU2012322613B2 (en) | 2011-10-14 | 2016-04-21 | Medimmune Limited | Pyrrolobenzodiazepines and targeted conjugates |
| EP2751110B1 (en) | 2011-10-14 | 2017-04-19 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases |
| EA029046B1 (ru) | 2011-10-14 | 2018-02-28 | Медимьюн Лимитед | Пирролобензодиазепины и промежуточные соединения для их получения, способы их синтеза |
| CN104540827B (zh) | 2012-04-30 | 2018-03-23 | Ucl商业有限公司 | 吡咯并苯并二氮杂卓 |
| AU2013255613B2 (en) | 2012-04-30 | 2017-06-22 | Medimmune Limited | Pyrrolobenzodiazepines |
| SG11201500087VA (en) | 2012-07-09 | 2015-02-27 | Genentech Inc | Immunoconjugates comprising anti-cd22 antibodies |
| AU2013288930A1 (en) | 2012-07-09 | 2014-12-04 | Genentech, Inc. | Immunoconjugates comprising anti-CD79b antibodies |
| KR20150039818A (ko) | 2012-08-02 | 2015-04-13 | 제넨테크, 인크. | 항-etbr 항체 및 면역접합체 |
| WO2014057118A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| WO2014057122A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| HRP20171264T1 (hr) | 2012-10-12 | 2017-10-20 | Adc Therapeutics Sa | Konjugati protutijela anti-her2-pirolobenzodiazepina |
| ES2713164T3 (es) | 2012-10-12 | 2019-05-20 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
| PT2906298T (pt) | 2012-10-12 | 2018-12-28 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpos |
| SMT201800346T1 (it) | 2012-10-12 | 2018-09-13 | Medimmune Ltd | Coniugati pirrolobenzodiazepina-anticorpo |
| EP2906249B1 (en) | 2012-10-12 | 2018-06-27 | MedImmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| SI2906253T1 (sl) | 2012-10-12 | 2018-11-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo proti PSMA |
| US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| CN110627797A (zh) | 2012-12-21 | 2019-12-31 | 麦迪穆有限责任公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| JP6307519B2 (ja) | 2012-12-21 | 2018-04-04 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピンおよびその結合体 |
| ES2731681T3 (es) | 2013-02-22 | 2019-11-18 | Abbvie Stemcentrx Llc | Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos |
| EP2968596B1 (en) | 2013-03-13 | 2019-03-06 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| AU2014230735B2 (en) | 2013-03-13 | 2018-03-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| WO2014174111A1 (en) | 2013-04-26 | 2014-10-30 | Pierre Fabre Medicament | Axl antibody-drug conjugate and its use for the treatment of cancer |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| US20160256561A1 (en) | 2013-10-11 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| HK1222577A1 (zh) | 2013-12-16 | 2017-07-07 | Genentech Inc. | 擬肽化合物及其抗體藥物偶聯物 |
| GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
-
2013
- 2013-10-11 ES ES13780099T patent/ES2713164T3/es active Active
- 2013-10-11 HU HUE18187765A patent/HUE052835T2/hu unknown
- 2013-10-11 PT PT181877655T patent/PT3470086T/pt unknown
- 2013-10-11 US US14/051,717 patent/US9415117B2/en active Active
- 2013-10-11 LT LTEP13780099.1T patent/LT2906248T/lt unknown
- 2013-10-11 TR TR2019/02494T patent/TR201902494T4/tr unknown
- 2013-10-11 MX MX2018013577A patent/MX366303B/es unknown
- 2013-10-11 SI SI201331325T patent/SI2906248T1/sl unknown
- 2013-10-11 SM SM20190144T patent/SMT201900144T1/it unknown
- 2013-10-11 CN CN201910645725.9A patent/CN110256469B/zh active Active
- 2013-10-11 CN CN201380053485.4A patent/CN104703630A/zh active Pending
- 2013-10-11 WO PCT/EP2013/071235 patent/WO2014057073A1/en not_active Ceased
- 2013-10-11 DK DK13780099.1T patent/DK2906248T3/en active
- 2013-10-11 CA CA3060520A patent/CA3060520C/en active Active
- 2013-10-11 EP EP13780099.1A patent/EP2906248B1/en active Active
- 2013-10-11 JP JP2015536139A patent/JP6367811B2/ja active Active
- 2013-10-11 CA CA2885315A patent/CA2885315C/en active Active
- 2013-10-11 SI SI201331845T patent/SI3470086T1/sl unknown
- 2013-10-11 SM SM20210265T patent/SMT202100265T1/it unknown
- 2013-10-11 RS RS20210002A patent/RS61294B1/sr unknown
- 2013-10-11 DK DK18187765.5T patent/DK3470086T3/da active
- 2013-10-11 PL PL13780099T patent/PL2906248T3/pl unknown
- 2013-10-11 BR BR112015008251-3A patent/BR112015008251B1/pt active IP Right Grant
- 2013-10-11 KR KR1020157009875A patent/KR20150083994A/ko not_active Ceased
- 2013-10-11 LT LTEP18187765.5T patent/LT3470086T/lt unknown
- 2013-10-11 NZ NZ745069A patent/NZ745069A/en unknown
- 2013-10-11 AU AU2013328674A patent/AU2013328674B2/en active Active
- 2013-10-11 KR KR1020197038868A patent/KR20200003278A/ko not_active Ceased
- 2013-10-11 PL PL18187765T patent/PL3470086T3/pl unknown
- 2013-10-11 PT PT13780099T patent/PT2906248T/pt unknown
- 2013-10-11 HU HUE13780099A patent/HUE043738T4/hu unknown
- 2013-10-11 HR HRP20190366TT patent/HRP20190366T1/hr unknown
- 2013-10-11 ES ES18187765T patent/ES2847050T3/es active Active
- 2013-10-11 RS RS20190024A patent/RS58203B1/sr unknown
- 2013-10-11 NZ NZ705910A patent/NZ705910A/en unknown
- 2013-10-11 KR KR1020197032333A patent/KR102138220B1/ko active Active
- 2013-10-11 MX MX2015004560A patent/MX362004B/es active IP Right Grant
- 2013-10-11 EP EP18187765.5A patent/EP3470086B1/en active Active
-
2015
- 2015-03-16 ZA ZA2015/01781A patent/ZA201501781B/en unknown
-
2018
- 2018-07-04 JP JP2018127804A patent/JP6516909B2/ja active Active
-
2019
- 2019-02-26 CY CY20191100233T patent/CY1121390T1/el unknown
-
2021
- 2021-01-22 HR HRP20210126TT patent/HRP20210126T1/hr unknown
- 2021-02-04 CY CY20211100096T patent/CY1123778T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245268B (en) | Pyrrolobenzodiazepines and their conjugates | |
| ZA201501781B (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| IL231796A0 (en) | Pyrrolobenzodiazepines and their conjugates | |
| ZA201602501B (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| IL241532B (en) | Pyrrolobenzodiazepines and their conjugates | |
| ZA201506668B (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| ZA201505753B (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| PT2920167T (pt) | Compostos de hidrazinil-indol e conjugados | |
| GB201317981D0 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| ZA201402404B (en) | Pyrrolobenzodiazepines and targeted conjugates | |
| ZA201206449B (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| IL238567A0 (en) | Antibodies against notch3 and antibody-drug conjugates | |
| ZA201407759B (en) | Pyrrolobenzodiazepines | |
| ZA201408043B (en) | Pyrrolobenzodiazepines | |
| GB201222541D0 (en) | Kiddibidet and pottibidet | |
| GB201202021D0 (en) | Co-sleeper and breastfeeder |